Lexaria Bioscience (LEXX) Institutional Ownership $1.45 +0.02 (+1.40%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.46 +0.01 (+0.34%) As of 02/21/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Lexaria Bioscience (NASDAQ:LEXX)CurrentInstitutional OwnershipPercentage13.06%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$3.47MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$1.19M Get LEXX Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexaria Bioscience stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LEXX Institutional Buying and Selling by Quarter Lexaria Bioscience Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Invenomic Capital Management LP410,731$863K0.0%-13.7%2.340% 2/13/2025 Raymond James Financial Inc.60,640$127K0.0%N/A0.346% 2/12/2025 Geode Capital Management LLC166,679$350K0.0%+10.8%0.950% 2/7/2025 HighTower Advisors LLC21,023$44K0.0%+61.4%0.120% 2/6/2025 Raymond James Financial Inc.60,640$127K0.0%N/A0.346% 1/28/2025 Byrne Asset Management LLC13,000$27K0.0%+132.1%0.074% 11/16/2024 Geode Capital Management LLC150,391$459K0.0%+31.0%0.951% 11/15/2024 XTX Topco Ltd18,626$57K0.0%+47.8%0.118% 11/15/2024 Invenomic Capital Management LP475,773$1.45M0.1%-7.4%3.007% 11/15/2024 HighTower Advisors LLC13,023$40K0.0%N/A0.082% Get the Latest News and Ratings for LEXX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. 8/15/2024 Armistice Capital LLC1,020,000$2.84M0.0%N/A7.916% 8/9/2024 Renaissance Technologies LLC22,800$63K0.0%N/A0.177% 5/16/2024 Invenomic Capital Management LP473,265$1.72M0.1%-35.3%3.672% 4/9/2024 Welch Group LLC24,000$87K0.0%N/A0.194% 2/14/2024 Invenomic Capital Management LP731,981$915K0.0%-4.2%7.011% 2/8/2024 Cowen AND Company LLC256,327$320K0.1%N/A2.455% 11/15/2023 Armistice Capital LLC889,272$889K0.0%N/A10.992% 8/14/2023 Invenomic Capital Management LP766,573$560K0.0%+62.0%9.476% 8/8/2022 Merit Financial Group LLC21,267$63K0.0%N/A0.357% 2/11/2022 Invenomic Capital Management LP359,113$1.45M0.3%+1.9%6.034% 11/15/2021MD Financial Management Inc.407,687$2.55M0.1%+15,078.2%7.988% 8/16/2021 Invenomic Capital Management LP317,110$2.22M0.5%+7.1%6.213% 8/13/2021 Renaissance Technologies LLC17,200$120K0.0%N/A0.337% 8/13/2021 Geode Capital Management LLC50,385$352K0.0%N/A0.987% 8/13/2021 Vanguard Group Inc.25,976$182K0.0%N/A0.509% 5/21/2021 Citadel Advisors LLC14,915$84K0.0%N/A0.292% 5/18/2021 Citadel Advisors LLC14,915$84K0.0%N/A0.292% (Data available from 1/1/2016 forward) LEXX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LEXX shares? During the previous two years, 10 institutional investors and hedge funds held shares of Lexaria Bioscience. The most heavily invested institutionals were Armistice Capital LLC ($2.84M), Invenomic Capital Management LP ($863K), Geode Capital Management LLC ($350K), Cowen AND Company LLC ($320K), Raymond James Financial Inc. ($127K), Welch Group LLC ($87K), and Renaissance Technologies LLC ($63K).Learn more on LEXX's institutional investors. What percentage of Lexaria Bioscience stock is owned by institutional investors? 13.06% of Lexaria Bioscience stock is owned by institutional investors. Learn more on LEXX's institutional investor holdings. Which institutional investors have been buying Lexaria Bioscience stock? Of the 10 institutional investors that purchased Lexaria Bioscience stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Armistice Capital LLC ($1.91M), Invenomic Capital Management LP ($293.47K), Cowen AND Company LLC ($256.33K), Raymond James Financial Inc. ($121.28K), Geode Capital Management LLC ($51.90K), Welch Group LLC ($24K), and Renaissance Technologies LLC ($22.80K). How much institutional buying is happening at Lexaria Bioscience? Institutional investors have bought a total of 2,713,492 shares in the last 24 months. This purchase volume represents approximately $4.90M in transactions. Which Lexaria Bioscience major shareholders have been selling company stock? The following institutional investors have sold Lexaria Bioscience stock in the last 24 months: Invenomic Capital Management LP ($393.91K). How much institutional selling is happening at Lexaria Bioscience? Institutional investors have sold a total of 393,909 shares in the last 24 months. This volume of shares sold represents approximately $1.23M in transactions. Related Companies CRBP Institutional Ownership MIST Institutional Ownership VTYX Institutional Ownership COYA Institutional Ownership TCRX Institutional Ownership CRDL Institutional Ownership EPRX Institutional Ownership SAVA Institutional Ownership DERM Institutional Ownership VIGL Institutional Ownership This page (NASDAQ:LEXX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
